SG11201508203TA - Enhancer of zeste homolog 2 inhibitors - Google Patents
Enhancer of zeste homolog 2 inhibitorsInfo
- Publication number
- SG11201508203TA SG11201508203TA SG11201508203TA SG11201508203TA SG11201508203TA SG 11201508203T A SG11201508203T A SG 11201508203TA SG 11201508203T A SG11201508203T A SG 11201508203TA SG 11201508203T A SG11201508203T A SG 11201508203TA SG 11201508203T A SG11201508203T A SG 11201508203TA
- Authority
- SG
- Singapore
- Prior art keywords
- enhancer
- inhibitors
- zeste homolog
- zeste
- homolog
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361817436P | 2013-04-30 | 2013-04-30 | |
US201361842038P | 2013-07-02 | 2013-07-02 | |
US201361907024P | 2013-11-21 | 2013-11-21 | |
US201461936460P | 2014-02-06 | 2014-02-06 | |
PCT/IB2014/061012 WO2014177982A1 (en) | 2013-04-30 | 2014-04-25 | Enhancer of zeste homolog 2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201508203TA true SG11201508203TA (en) | 2015-11-27 |
Family
ID=50877537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201508203TA SG11201508203TA (en) | 2013-04-30 | 2014-04-25 | Enhancer of zeste homolog 2 inhibitors |
Country Status (20)
Country | Link |
---|---|
US (2) | US9505745B2 (en) |
EP (1) | EP2991980B1 (en) |
JP (1) | JP6373973B2 (en) |
KR (1) | KR20160003115A (en) |
CN (1) | CN105308038B (en) |
AU (1) | AU2014261075B2 (en) |
BR (1) | BR112015027527A2 (en) |
CA (1) | CA2910873A1 (en) |
CL (1) | CL2015003200A1 (en) |
DO (1) | DOP2015000270A (en) |
EA (1) | EA030196B1 (en) |
ES (1) | ES2717680T3 (en) |
HK (1) | HK1214815A1 (en) |
MX (1) | MX2015015144A (en) |
NZ (1) | NZ630205A (en) |
PE (1) | PE20151981A1 (en) |
PH (1) | PH12015502414A1 (en) |
SG (1) | SG11201508203TA (en) |
WO (1) | WO2014177982A1 (en) |
ZA (1) | ZA201507398B (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9085583B2 (en) * | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
SG11201508203TA (en) * | 2013-04-30 | 2015-11-27 | Glaxosmithkline Ip No 2 Ltd | Enhancer of zeste homolog 2 inhibitors |
US9556157B2 (en) | 2013-07-10 | 2017-01-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
KR102352388B1 (en) | 2014-02-06 | 2022-01-17 | 헵테얼즈 테라퓨틱스 리미티드 | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
CA2965729A1 (en) * | 2014-10-28 | 2016-05-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
TW201636344A (en) * | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Inhibitors of EZH2 |
UY36758A (en) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | INHIBITORS OF THE ZESTE 2 HOMOLOGIST POTENTIATOR |
KR20180042356A (en) | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | How to treat cancer |
TW201718598A (en) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Inhibitors of EZH2 |
EP3370725A4 (en) * | 2015-11-06 | 2019-07-03 | Epizyme, Inc. | Pediatric dosing for treatment of cancer with an ezh2 inhibitor |
ES2760510T3 (en) | 2015-11-19 | 2020-05-14 | Jiangsu Hengrui Medicine Co | Derived from benzofuran, method of preparing it and using it in medicine |
CR20180521A (en) | 2016-05-05 | 2019-01-15 | Glaxosmithkline Ip No 2 Ltd | INHIBITORS OF THE ZESTE 2 HOMOLOGIST POTENTIATOR |
US20170337814A1 (en) * | 2016-05-20 | 2017-11-23 | Donald Edward Morgan | Safety alerting drivers device and system |
WO2018045971A1 (en) | 2016-09-07 | 2018-03-15 | 上海海和药物研究开发有限公司 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof |
WO2018125983A1 (en) | 2016-12-30 | 2018-07-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
PT3746446T (en) | 2018-01-31 | 2022-07-18 | Mirati Therapeutics Inc | Prc2 inhibitors |
CA3104209A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
TWI762939B (en) * | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | BTK inhibitor cyclic derivatives, preparation method and pharmaceutical application thereof |
KR20220066892A (en) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | Combination therapy of T cell therapy and Zest homologue 2 enhancer (EH2) inhibitor and related methods |
CN110964200A (en) * | 2019-12-19 | 2020-04-07 | 新纳奇材料科技江苏有限公司 | Preparation method of hydroxyl-terminated polysiloxane based on polysiloxane distillate |
CN114787143A (en) * | 2019-12-23 | 2022-07-22 | 四川海思科制药有限公司 | ZESTE enhancer homolog 2 inhibitors and uses thereof |
CN111233768B (en) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | Preparation method of 3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester |
TW202404581A (en) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek inhibitors and uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080293716A1 (en) * | 2004-01-30 | 2008-11-27 | Smithkline Beecham Corporation | Chemical Compounds |
JP2007531757A (en) * | 2004-03-30 | 2007-11-08 | カイロン コーポレイション | Substituted thiophene derivatives as anticancer agents |
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
MX2012001413A (en) * | 2009-08-07 | 2012-03-21 | Merck Patent Gmbh | Novel azaheterocyclic compounds. |
SI2566327T1 (en) | 2010-05-07 | 2017-07-31 | Glaxosmithkline Llc | Indoles |
WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
ES2528269T3 (en) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
JP5908493B2 (en) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Indole |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
TWI598336B (en) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | Substituted benzene compounds |
US9730925B2 (en) * | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
RU2658911C2 (en) | 2012-04-13 | 2018-06-26 | Эпизайм, Инк. | Salt form of human histone methyltranserase ezh2 inhibitor |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
SG11201508203TA (en) * | 2013-04-30 | 2015-11-27 | Glaxosmithkline Ip No 2 Ltd | Enhancer of zeste homolog 2 inhibitors |
-
2014
- 2014-04-25 SG SG11201508203TA patent/SG11201508203TA/en unknown
- 2014-04-25 US US14/787,866 patent/US9505745B2/en active Active
- 2014-04-25 JP JP2016511152A patent/JP6373973B2/en not_active Expired - Fee Related
- 2014-04-25 WO PCT/IB2014/061012 patent/WO2014177982A1/en active Application Filing
- 2014-04-25 CN CN201480033093.6A patent/CN105308038B/en not_active Expired - Fee Related
- 2014-04-25 NZ NZ630205A patent/NZ630205A/en not_active IP Right Cessation
- 2014-04-25 KR KR1020157033651A patent/KR20160003115A/en not_active Application Discontinuation
- 2014-04-25 CA CA2910873A patent/CA2910873A1/en not_active Abandoned
- 2014-04-25 PE PE2015002298A patent/PE20151981A1/en not_active Application Discontinuation
- 2014-04-25 BR BR112015027527A patent/BR112015027527A2/en not_active IP Right Cessation
- 2014-04-25 EA EA201592068A patent/EA030196B1/en not_active IP Right Cessation
- 2014-04-25 EP EP14727619.0A patent/EP2991980B1/en active Active
- 2014-04-25 ES ES14727619T patent/ES2717680T3/en active Active
- 2014-04-25 AU AU2014261075A patent/AU2014261075B2/en not_active Ceased
- 2014-04-25 MX MX2015015144A patent/MX2015015144A/en unknown
-
2015
- 2015-10-06 ZA ZA2015/07398A patent/ZA201507398B/en unknown
- 2015-10-19 PH PH12015502414A patent/PH12015502414A1/en unknown
- 2015-10-30 DO DO2015000270A patent/DOP2015000270A/en unknown
- 2015-10-30 CL CL2015003200A patent/CL2015003200A1/en unknown
-
2016
- 2016-03-09 HK HK16102708.1A patent/HK1214815A1/en unknown
- 2016-10-13 US US15/292,200 patent/US9790212B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2014261075A1 (en) | 2015-11-05 |
DOP2015000270A (en) | 2016-02-15 |
US20160102083A1 (en) | 2016-04-14 |
EP2991980B1 (en) | 2019-01-02 |
WO2014177982A1 (en) | 2014-11-06 |
EA030196B1 (en) | 2018-07-31 |
AU2014261075B2 (en) | 2017-01-19 |
ES2717680T3 (en) | 2019-06-24 |
US9505745B2 (en) | 2016-11-29 |
PE20151981A1 (en) | 2016-01-14 |
CN105308038B (en) | 2018-05-29 |
EA201592068A1 (en) | 2016-05-31 |
KR20160003115A (en) | 2016-01-08 |
JP6373973B2 (en) | 2018-08-15 |
CL2015003200A1 (en) | 2016-04-22 |
NZ630205A (en) | 2017-03-31 |
US20170029412A1 (en) | 2017-02-02 |
CN105308038A (en) | 2016-02-03 |
MX2015015144A (en) | 2016-02-18 |
JP2016517878A (en) | 2016-06-20 |
PH12015502414A1 (en) | 2016-02-22 |
BR112015027527A2 (en) | 2017-07-25 |
EP2991980A1 (en) | 2016-03-09 |
US9790212B2 (en) | 2017-10-17 |
HK1214815A1 (en) | 2016-08-05 |
ZA201507398B (en) | 2017-01-25 |
CA2910873A1 (en) | 2014-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214815A1 (en) | Enhancer of zeste homolog 2 inhibitors zeste 2 | |
IL251584B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL279682A (en) | Benzoquinolone inhibitors of vmat2 | |
IL246902A0 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
HK1222390A1 (en) | Polymorph of syk inhibitors syk | |
EP2931707A4 (en) | Enhancer of zeste homolog 2 inhibitors | |
HK1222329A1 (en) | Formulation of syk inhibitors syk | |
IL262701A (en) | Enhancer of zeste homolog 2 inhibitors | |
GB201410735D0 (en) | Method of inhibiting DYRK1B | |
HK1222339A1 (en) | Inhibitors of metallo-ss-lactamase-enzymes -- | |
IL243610B (en) | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | |
HK1221645A1 (en) | Benzoquinolone inhibitors of vmat2 vmat2 | |
IL240763B (en) | Halogenopyrazoles as inhibitors of therombin | |
SG10201705899XA (en) | Prevention & treatment of neuropathy | |
GB201320366D0 (en) | Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein | |
HK1204865A1 (en) | Composition for elimination of troublesome varmints |